Promis Neurosciences Inc (PMN) Stock Price, Quote & News

Company Profile

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer'...

Industry: Biotechnology

Sector: Healthcare

Phone: 416 847 6898

Fax: 416 847 6899

Website: www.promisneurosciences.com

Address:

1920 Yonge Street, Suite 200, Toronto, Canada

Kgra Feb. 4 at 3:20 AM

$PMN this is about the lamest board I’m on, I bought in 3 weeks ago almost doubled my money and yet this board still has no action , market cap 30 m , They just raised 75m with 100m in warrants , when will word get out ?

0 · Reply

Hunterman2 Feb. 3 at 4:54 PM

i need to get all my cash back from here $PMN to go all in fir the golden ticket here $ABVE Buy! Buy! Buy!

0 · Reply

Hunterman2 Feb. 3 at 4:50 PM

$PMN they screw me over with the RS last year. A few thousand shares now become a few hundred. I have no more cash to put on this. Hoping the rise continue all the way to $40+ soon.

1 · Reply

topstockalerts Feb. 3 at 4:41 PM

$PMN This one was on watch and now it’s moving 👀. Buyers stepped in right on time. That’s how breakouts start.

0 · Reply

Sunny3999 Feb. 3 at 4:38 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger. News with $175 Million financing last week! $JNJ $LLY $PFE $PMN $REGN

0 · Reply

Cellsci Feb. 3 at 4:32 PM

$PMN others loving also

0 · Reply

WadehN21 Feb. 3 at 4:32 PM

$PMN Bears are here... good sign lol

0 · Reply

Sunny3999 Feb. 3 at 4:31 PM

0 · Reply

Sunny3999 Feb. 3 at 4:29 PM

0 · Reply

Champing Feb. 3 at 4:28 PM

$PMN A big offering soon. Offerings please

1 · Reply

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

Dec 18, 2025, 7:30 AM EST - 6 weeks ago

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer's Disease

Dec 10, 2025, 7:30 AM EST - 7 weeks ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

Dec 1, 2025, 7:30 AM EST - 2 months ago

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer's trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

Dec 1, 2025, 7:00 AM EST - 2 months ago

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

Nov 24, 2025, 8:00 AM EST - 2 months ago

ProMIS Neurosciences Announces Reverse Stock Split

Nov 12, 2025, 7:00 AM EST - 2 months ago

ProMIS Neurosciences Announces Third Quarter 2025 Financial Results & Corporate Highlights

Nov 3, 2025, 4:05 PM EST - 3 months ago

ProMIS Neurosciences to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 22, 2025, 7:30 AM EDT - 3 months ago

ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group

Sep 3, 2025, 7:00 AM EDT - 5 months ago

ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer's Trial of PMN310

Aug 13, 2025, 7:00 AM EDT - 6 months ago

ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights

Jul 29, 2025, 8:00 AM EDT - 6 months ago

ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer's Association International Conference

Jul 28, 2025, 7:00 AM EDT - 6 months ago

ProMIS Neurosciences Announces Private Placement Financing

Jul 21, 2025, 8:00 AM EDT - 7 months ago

ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer's Disease

Jun 17, 2025, 7:00 AM EDT - 8 months ago

ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

May 12, 2025, 7:30 AM EDT - 9 months ago

ProMIS Neurosciences Announces First Quarter 2025 Financial Results

Mar 31, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Announces Full Year 2024 Financial Results and Recent Highlights

Mar 24, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference

Mar 13, 2025, 7:00 AM EDT - 11 months ago

ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting

Mar 11, 2025, 7:30 AM EDT - 11 months ago

ProMIS Neurosciences to Participate in the 37th Annual Roth Conference

Feb 25, 2025, 7:00 AM EST - 1 year ago

ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease

Jan 29, 2025, 7:30 AM EST - 1 year ago

ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference

Jan 13, 2025, 10:30 AM EST - 1 year ago

ProMIS Neurosciences Issues Letter to Shareholders

Nov 14, 2024, 9:15 AM EST - 1 year ago

ProMIS Neurosciences Announces Third Quarter 2024 Financial Results and Recent Highlights

Oct 30, 2024, 8:00 AM EDT - 1 year ago

ProMIS Neurosciences Presents Positive Data from PMN310 Phase1a Clinical Trial at the 17th Clinical Trials on Alzheimer's Disease Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Showcase PMN310's Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences

Sep 5, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024

Jul 30, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer's Association International Conference

Jul 26, 2024, 8:35 AM EDT - 1 year ago

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

Jul 26, 2024, 8:30 AM EDT - 1 year ago

ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing

May 14, 2024, 4:01 PM EDT - 1 year ago

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Apr 30, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies

Apr 9, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS

Apr 4, 2024, 7:00 AM EDT - 1 year ago

ProMIS Neurosciences to Present in Upcoming Investor Conferences in April

Apr 1, 2024, 4:15 PM EDT - 2 years ago

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights

Mar 11, 2024, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio

Feb 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference

Jan 22, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine

Jan 3, 2024, 7:00 AM EST - 2 years ago

ProMIS Neurosciences, Inc. Announces Leadership Transition

Dec 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Announces Publication on Novel Target for ALS

Nov 20, 2023, 7:00 AM EST - 2 years ago

ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer's Disease

Nov 14, 2023, 4:30 PM EST - 2 years ago

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Sep 8, 2023, 7:00 AM EDT - 2 years ago

ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

Sep 6, 2023, 12:18 PM EDT - 2 years ago

ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 21, 2023, 4:12 PM EDT - 2 years ago

ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

Aug 14, 2023, 5:33 PM EDT - 2 years ago

ProMIS Neurosciences Announces Second Quarter 2023 Financial Results and Recent Highlights

Jul 17, 2023, 7:00 AM EDT - 2 years ago

ProMIS Showcases Preclinical Data at the Alzheimer's Association International Conference 2023 on Computationally-Derived Antibody and Vaccine from Alzheimer's Pipeline

Jul 14, 2023, 7:45 AM EDT - 2 years ago

ProMIS Announces Completion of Continuance

Jul 10, 2023, 7:55 AM EDT - 2 years ago

ProMIS Neurosciences to Consolidate Trading on the Nasdaq Exchange

Kgra Feb. 4 at 3:20 AM

0 · Reply

Hunterman2 Feb. 3 at 4:54 PM

i need to get all my cash back from here $PMN to go all in fir the golden ticket here $ABVE Buy! Buy! Buy!

0 · Reply

Hunterman2 Feb. 3 at 4:50 PM

$PMN they screw me over with the RS last year. A few thousand shares now become a few hundred. I have no more cash to put on this. Hoping the rise continue all the way to $40+ soon.

1 · Reply

topstockalerts Feb. 3 at 4:41 PM

$PMN This one was on watch and now it’s moving 👀. Buyers stepped in right on time. That’s how breakouts start.

0 · Reply

Sunny3999 Feb. 3 at 4:38 PM

0 · Reply

Cellsci Feb. 3 at 4:32 PM

$PMN others loving also

0 · Reply

WadehN21 Feb. 3 at 4:32 PM

$PMN Bears are here... good sign lol

0 · Reply

Sunny3999 Feb. 3 at 4:31 PM

0 · Reply

Sunny3999 Feb. 3 at 4:29 PM

0 · Reply

Champing Feb. 3 at 4:28 PM

$PMN A big offering soon. Offerings please

1 · Reply

Champing Feb. 3 at 4:27 PM

$PMN 8.76$ After hours Exit Now!

0 · Reply

Sunny3999 Feb. 3 at 4:18 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $HUM $MET $MSBI $UNH

0 · Reply

Sunny3999 Feb. 3 at 4:18 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $CNC $CVS $UNH $WBA

0 · Reply

Sunny3999 Feb. 3 at 4:18 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $AAPL $GOOG $META $MSFT

0 · Reply

Sunny3999 Feb. 3 at 4:17 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $C $RY $SCHF $WFC

0 · Reply

Sunny3999 Feb. 3 at 4:16 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ABBV $BMY $MRK $SNY

0 · Reply

Sunny3999 Feb. 3 at 4:16 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $CAH $CI $COR $MCK

0 · Reply

Sunny3999 Feb. 3 at 4:15 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ACET $PAVM $PMNT $RVPH

0 · Reply

Sunny3999 Feb. 3 at 4:15 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $BAC $C $GS $MS

0 · Reply

Sunny3999 Feb. 3 at 4:15 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ABC $AMZN $COST $WMT

0 · Reply

Sunny3999 Feb. 3 at 4:14 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $ABBV $CELG $JNJ $PFE

0 · Reply

Sunny3999 Feb. 3 at 4:13 PM

$PMN MCAP of $35 Million for an Alzheimer solution with Fast Track designation and DSMB approval without ARIA! This is a 1 billion MCAP in the making easily a 10 bagger $CAH $CI $COR $MCK

0 · Reply

Market Cap	30.48M
Revenue (ttm)	0.00
Net Income (ttm)	2.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	238,300
Avg Vol	195,227
Day's Range	N/A - N/A
Shares Out	2.15M
Stochastic %K	66%
Beta	-0.10
Analysts	Strong Sell
Price Target	$26.50